Core Insights - Ocugen is advancing its gene therapy pipeline, particularly focusing on OCU400 for retinitis pigmentosa (RP) and OCU410 for Stargardt disease, with significant milestones expected in the coming years [1][2][3][4]. Group 1: OCU400 Development - The Phase III liMeliGhT trial for OCU400 has completed enrollment with 140 patients, and top-line data is anticipated in Q1 2027, which is expected to support a biologics license application (BLA) filing and potential approval in 2027 [1][8]. - OCU400 is designed as a modifier gene therapy targeting multiple mutations in RP, potentially addressing 98% to 99% of RP patients, compared to the only approved therapy that targets only 1% to 2% of patients [2][3]. Group 2: Financial Performance - In 2025, research and development expenses rose to $39.8 million, with a net loss of $0.23 per share, compared to $32.1 million and $0.20 per share in 2024 [6][28]. - The company has extended its cash runway into late 2026, with potential extension into Q2 2027 if $30 million in warrants are exercised [6][24]. Group 3: Stargardt and Geographic Atrophy Programs - The GARDian3 trial for Stargardt disease is ahead of schedule, with top-line data expected in Q2 2027, and the European Medicines Agency has confirmed that data from a single U.S. trial can support a European filing [7][12][13]. - Preliminary Phase II data for OCU410 in geographic atrophy showed a 46% reduction in lesion growth at 12 months, with plans for Phase III initiation in 2026 [17][18]. Group 4: Business Development and Partnerships - Ocugen has executed its first regional licensing agreement with Kwangdong Pharmaceutical for exclusive rights to OCU400 in Korea, which includes upfront fees and royalties [22]. - The company has created a wholly owned subsidiary, Ocucelix, to focus on regenerative cell therapy assets, aiming to maximize value for shareholders [21]. Group 5: Upcoming Milestones - Key upcoming milestones include the completion of OCU410ST enrollment in early 2026, initiation of Phase III for OCU410, and the start of rolling BLA submission for OCU400 in Q3 2026 [25].

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $10.7 million, up from $8.3 million in Q4 2024, indicating a year-over-year increase of approximately 29% [22] - General and administrative expenses for Q4 2025 were $6.1 million, slightly down from $6.3 million in Q4 2024 [22] - The net loss per common share for Q4 2025 was $0.06, compared to a net loss of $0.05 per common share in Q4 2024 [22] - For the full year 2025, research and development expenses totaled $39.8 million, up from $32.1 million in 2024, representing a 24% increase [23] - General and administrative expenses for the full year 2025 were $27.6 million, compared to $26.7 million in 2024 [23] - The net loss per common share for the full year 2025 was $0.23, compared to $0.20 in 2024 [23] - Current cash and cash equivalents extend the runway into Q4 2026, with a recent raise of $22.5 million through a direct offering [23][24] Business Line Data and Key Metrics Changes - Enrollment for the OCU400 phase III liMeliGhT trial is complete, with top-line data expected in Q1 2027 [7] - The OCU400 trial enrolled 140 patients, with a primary endpoint focused on visual function improvement over 12 months [7] - Positive long-term data from the OCU400 phase I/II trial showed a sustained two-line gain in low luminance visual acuity [8] - OCU410ST is targeting over 1,200 mutations associated with Stargardt disease, with phase II/III data anticipated in Q2 2027 [10] - OCU410 demonstrated a 46% reduction in lesion growth at 12 months, significantly outperforming existing therapies [16] Market Data and Key Metrics Changes - The OCU400 program targets a broader patient population, addressing 98%-99% of retinitis pigmentosa patients compared to existing therapies that only target RPE65 mutations [6] - The OCU410 program addresses a significant market opportunity with approximately 2-3 million geographic atrophy patients in the U.S. and Europe combined [15] - The OCU410ST program has received Rare Pediatric Disease Designation, enhancing its regulatory positioning [11] Company Strategy and Development Direction - The company aims to file three Biologics License Applications (BLAs) in the next three years, with a focus on transitioning into a commercial-stage company [4][18] - Regional partnerships are being pursued to maximize patient reach while retaining commercial rights in larger markets [9] - The company is strengthening its leadership team to support its transition towards regulatory approvals and commercialization [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting timelines for clinical trials and regulatory submissions, emphasizing the transformative year of 2025 [4][21] - The company is focused on addressing significant unmet medical needs in the gene therapy space, particularly for blindness diseases [4][18] - Management highlighted the importance of upcoming data releases and milestones in 2026, which are expected to drive the company's growth [18][85] Other Important Information - The company has established Ocucelix as a wholly-owned subsidiary for regenerative cell therapy assets, aiming for independence through financing [18] - The company is actively working on its inhaled vaccine candidate, OCU500, with a phase I trial expected to start in Q2 2026 [18] Q&A Session Summary Question: Confidence in data turnaround for the liMeliGhT study - Management expressed confidence in meeting the timeline for releasing top-line data in Q1 2027 [26][28] Question: Modifications for the navigation assessment course - The primary metric for RP was chosen for its sensitivity and specificity, validated by FDA approval [28][29] Question: Impact of other therapies on OCU410ST - Management believes OCU410ST will set the standard of care, regardless of other therapies entering the market [30][32] Question: FDA feedback on CMC part of the filing - CMC feedback is expected to be received after the final clinical module is filed [41] Question: Commercial value of the Ellipsoid Zone as an endpoint - The Ellipsoid Zone is gaining traction among clinicians and may provide meaningful information for commercial claims [46][48] Question: Characteristics of responders in the OCU410 program - Baseline characteristics were uniform across groups, with no unique criteria identified yet [80][82]

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $10.7 million, up from $8.3 million in Q4 2024, indicating a 29% increase [22] - General and administrative expenses for Q4 2025 were $6.1 million, slightly down from $6.3 million in Q4 2024 [22] - The net loss per common share for Q4 2025 was $0.06, compared to a net loss of $0.05 per common share in Q4 2024 [22] - For the full year 2025, research and development expenses totaled $39.8 million, up from $32.1 million in 2024, reflecting a 24% increase [23] - General and administrative expenses for the full year 2025 were $27.6 million, compared to $26.7 million in 2024 [23] - The net loss per common share for the full year 2025 was $0.23, compared to $0.20 in 2024 [23] Business Line Data and Key Metrics Changes - Enrollment for the OCU400 Phase 3 liMeliGhT trial is complete, with top-line data expected in Q1 2027 [7] - The OCU400 trial enrolled 140 patients, with a primary endpoint of 12-month change in visual function assessed by LDNA [7] - OCU410ST is ahead of schedule, with top-line phase 2/3 data anticipated in Q2 2027 [10] - OCU410 demonstrated a 46% reduction in lesion growth at 12 months, significantly outperforming existing therapies [16] Market Data and Key Metrics Changes - The OCU400 program targets a broader patient population, addressing 98%-99% of retinitis pigmentosa patients, compared to existing therapies that target only 1%-2% [6] - OCU410 is positioned to address a significant market opportunity with approximately 2 million to 3 million geographic atrophy patients in the U.S. and Europe combined [15] Company Strategy and Development Direction - The company aims to file three Biologics License Applications (BLAs) in the next three years, with a focus on transitioning into a commercial stage company [4][18] - Ocugen is pursuing regional partnerships to maximize patient reach while retaining full commercial rights in larger markets [9] - The establishment of Ocucelix as a subsidiary for regenerative cell therapy assets indicates a strategic move to enhance shareholder value [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting timelines for clinical trials and regulatory submissions, emphasizing the transformative year of 2025 [4][21] - The company is focused on disciplined resource allocation as it advances toward late-stage development and potential commercialization [20] - Management highlighted the importance of upcoming milestones in 2026, including the completion of enrollment for OCU410ST and the initiation of phase 3 for OCU410 [18] Other Important Information - The company raised $22.5 million through an underwritten registered direct offering, extending its cash runway into Q4 2026 [23] - If $30 million in warrants from a prior raise are exercised, the cash runway could extend into Q2 2027 [24] Q&A Session Summary Question: Confidence in data turnaround for the liMeliGhT study - Management expressed confidence in meeting the timeline for releasing top-line data in Q1 2027 [26][28] Question: Modifications for the navigation assessment course - The proprietary mobility test used is validated and approved by the FDA, designed to capture real change in functional outcomes [28][29] Question: Impact of other therapies on OCU410ST opportunity - Management believes OCU410ST will set the standard of care, regardless of other therapies entering the market first [30][32] Question: FDA feedback on CMC part of the filing - CMC feedback is typically received after the final clinical module is filed, and management is planning to file this year [41] Question: Commercial value of the Ellipsoid Zone as an endpoint - The Ellipsoid Zone is gaining traction among clinicians and could provide meaningful information for commercial claims [46][48] Question: Characteristics of responders in the OCU410 program - Baseline characteristics were uniform across groups, with no unique criteria identified at this point [81]

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $10.7 million, up from $8.3 million in Q4 2024, while general and administrative expenses decreased slightly to $6.1 million from $6.3 million in the same period [22] - For the full year 2025, research and development expenses totaled $39.8 million compared to $32.1 million in 2024, and general and administrative expenses increased to $27.6 million from $26.7 million [23] - The net loss per common share for Q4 2025 was $0.06, compared to a loss of $0.05 in Q4 2024, and for the full year, the net loss was $0.23 compared to $0.20 in 2024 [22][23] Business Line Data and Key Metrics Changes - OCU400's Phase 3 liMeliGhT trial has completed enrollment, with top-line data expected in Q1 2027, which will support the BLA filing anticipated in 2027 [6][8] - OCU410ST for Stargardt disease is ahead of schedule, with top-line data expected in Q2 2027, and the program has received Rare Pediatric Disease Designation [10][11] - OCU410 for geographic atrophy has shown a 46% reduction in lesion growth at 12 months, significantly outperforming existing therapies [16] Market Data and Key Metrics Changes - The U.S. and European markets for retinitis pigmentosa (RP) include approximately 300,000 patients, while Stargardt disease affects about 100,000 patients in the U.S. and Europe combined [5][10] - The estimated market for geographic atrophy (GA) includes 2 million to 3 million patients in the U.S. and Europe [15] Company Strategy and Development Direction - The company aims to file three BLAs in the next three years, focusing on advancing its gene therapy programs into commercialization [18] - Ocugen is pursuing regional partnerships to maximize patient reach while retaining full commercial rights in larger markets [9] - The company has strengthened its leadership team to support its transition into a commercial stage company [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting timelines for clinical trials and emphasized the importance of upcoming data releases as catalysts for growth [26][30] - The company is focused on addressing significant unmet medical needs in the gene therapy space, particularly for conditions like Stargardt disease and GA [30][31] Other Important Information - Ocugen's cash runway extends into Q4 2026, bolstered by a recent $22.5 million capital raise [23][24] - The company has established Ocucelix as a subsidiary for regenerative cell therapy assets, aiming for independent financing [18] Q&A Session Summary Question: Confidence in data turnaround for liMeliGhT study - Management expressed confidence in meeting the timeline for releasing top-line data in Q1 2027 [26] Question: Modifications for navigation assessment course - The primary metric for RP was chosen for its sensitivity and specificity, validated by FDA [27][28] Question: Impact of other therapies on OCU410ST - Management believes OCU410ST will set the standard of care, regardless of other therapies entering the market [30][31] Question: CMC feedback timeline for OCU400 - CMC feedback from FDA is expected after the final clinical module is filed [41] Question: Commercial value of Ellipsoid Zone as an endpoint - The Ellipsoid Zone is gaining traction among clinicians and may provide meaningful information for commercial claims [46][48] Question: Characteristics of responders in OCU410 program - Baseline characteristics were uniform across groups, with no unique criteria identified yet [80]

Core Insights - Ocugen is progressing with its late-stage modifier gene therapies, targeting BLA/MAA filings in 2026 and 2027, with significant enrollment milestones achieved in ongoing clinical trials [2][3][4] Clinical Development - The OCU400 Phase 3 liMeLiGhT clinical trial is nearing completion, with 50% enrollment achieved, and is on track for BLA and MAA submissions in 2026 [3][6] - The OCU410ST Phase 2/3 GARDian3 pivotal confirmatory trial is also progressing well, with the EMA accepting a single U.S.-based trial for MAA submission [4][6] - Ocugen's gene-agnostic approach aims to treat retinitis pigmentosa (RP), which affects approximately 300,000 individuals in the U.S. and Europe, with a single therapeutic method addressing multiple genetic mutations [3][12] Licensing and Financial Agreements - Ocugen has entered an exclusive licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea, which includes potential upfront and milestone payments totaling up to $7.5 million, plus sales milestones projected to reach $180 million in the first decade [2][6] - The company will receive a 25% royalty on net sales from Kwangdong and is responsible for manufacturing and supplying OCU400 [2][6] Financial Performance - For Q3 2025, Ocugen reported total revenue of $1.75 million, an increase from $1.14 million in Q3 2024, while total operating expenses rose to $19.4 million from $14.4 million in the same period [10][19] - The net loss for Q3 2025 was $20.05 million, compared to a net loss of $12.97 million in Q3 2024 [19] - As of September 30, 2025, the company had cash and cash equivalents totaling $32.9 million, down from $58.8 million at the end of 2024 [12][19] Future Outlook - Upcoming milestones include the release of full data from the OCU410 Phase 2 trial in Q1 2026, interim data from the OCU410ST trial in mid-2026, and top-line data from the OCU400 Phase 3 trial in Q4 2026 [7][12] - The company is actively pursuing additional financing and strategic partnerships to support its commercialization efforts [7]

Core Viewpoint - Ocugen, Inc. is advancing its gene therapy programs for blindness diseases, with significant clinical trial progress and strategic partnerships aimed at supporting future Biologics License Application (BLA) filings [2][11]. Business Development - The company is focused on securing strategic partnerships, including a licensing agreement for OCU400 in Korea, which includes sales milestones of $1 million for every $15 million in net sales and a 25% royalty on net sales [3]. - A proposed reverse merger with OrthoCellix and Carisma Therapeutics aims to create a Nasdaq-listed regenerative cell therapy company, enhancing focus on orthopedic diseases and the NeoCart technology [2]. Clinical Trials and Designations - The FDA has granted Rare Pediatric Disease Designation (RPDD) to OCU410ST for Stargardt disease, highlighting the unmet medical need for this condition affecting approximately 100,000 people in the U.S. and Europe [4]. - The OCU410ST Phase 2/3 GARDian3 clinical trial has commenced, building on positive results from the Phase 1 trial, which showed a 48% slower lesion growth in treated eyes [5]. - Preliminary data from the OCU410 Phase 1 ArMaDa trial indicated a 23% slower geographic atrophy lesion growth and a 2-line/10-letter gain in visual acuity [6]. Financial Performance - As of June 30, 2025, the company reported cash and cash equivalents of $27.3 million, down from $58.8 million at the end of 2024, providing a cash runway into the first quarter of 2026 [16]. - Total operating expenses for Q2 2025 were $15.2 million, a decrease from $16.6 million in Q2 2024, with research and development expenses at $8.4 million [16][25]. - The company reported a net loss of $0.05 per common share for Q2 2025, compared to a net loss of $0.06 per common share in the same period of 2024 [16][26].

Financial Data and Key Metrics Changes - Research and development expenses for Q1 2025 were $9.5 million, up from $6.8 million in Q1 2024, indicating a significant increase in investment in R&D [21] - General and administrative expenses for Q1 2025 were $6.5 million, slightly up from $6.4 million in the same period of 2024 [22] - The net loss for Q1 2025 was approximately $15.3 million, or $0.05 net loss per share, compared to a net loss of approximately $11.9 million, or $0.05 net loss per share, in Q1 2024 [22] - Cash and restricted cash totaled $38.1 million as of March 31, 2025, down from $58.8 million as of December 31, 2024, indicating a decrease in liquidity [22] Business Line Data and Key Metrics Changes - The company is advancing three gene therapies through clinical trials, with a focus on modifier gene therapy, which targets diseases with large patient populations [7][9] - OCU400 has shown positive two-year long-term safety and efficacy data, demonstrating a statistically significant improvement in visual function [12] - OCU410 is designed to address multiple pathways in dry AMD, with a goal of providing a one-time therapy for millions suffering from the condition [17] Market Data and Key Metrics Changes - OCU400 has the potential to treat approximately 300,000 RP patients in the U.S. and EU, and 1.6 million patients globally, using a gene-agnostic approach [11] - The company is planning to initiate a Phase III clinical trial for OCU410 in 2026, targeting a BLA submission in 2028 [10] Company Strategy and Development Direction - The company aims to file three biologics license applications (BLA) in the next three years, focusing on modifier gene therapies that offer potential cures for life [7] - The strategy includes building manufacturing capabilities in-house to support future commercial launches, with plans for a second site in the U.S. [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress of their gene therapy programs and the significance of upcoming milestones, emphasizing the mission to address unmet medical needs for patients facing vision loss [58] - The company is actively engaging with regulatory agencies to align clinical trial designs and expedite the approval process for their therapies [39] Other Important Information - The company is in discussions regarding developmental funding for its vaccine technology for influenza [20] - The investigational new drug application for OCU500 is in effect, with plans for a Phase I clinical trial to begin in Q2 2025 [20] Q&A Session Summary Question: Enrollment status for the Limelight study and filing targets - Management confirmed that enrollment for the OCU400 Phase III trial is on track for the first half of 2025, with a BLA submission expected a year from now [28] Question: Manufacturing capabilities for filing and commercialization - Management stated that process validations at commercial scale are on target for completion this year, with plans to bring manufacturing in-house after initial commercial launch [30][31] Question: Update on the OCU200 program - Management indicated that a clinical update, including preliminary efficacy and safety data, is expected before the end of the year [34] Question: Clarification on European regulations for OCU400 - Management clarified that no additional trials are required in Europe if approval is obtained in the U.S., as the trial has sufficient representation for global mutations [55]

Financial Data and Key Metrics Changes - Research and development expenses for Q1 2025 were $9.5 million, up from $6.8 million in Q1 2024, indicating a significant increase in investment in R&D [22] - General and administrative expenses for Q1 2025 were $6.5 million, slightly up from $6.4 million in the same period of 2024 [23] - The net loss for Q1 2025 was approximately $15.3 million, or $0.05 net loss per share, compared to a net loss of approximately $11.9 million, or $0.05 net loss per share, in Q1 2024 [23] - Cash and restricted cash totaled $38.1 million as of March 31, 2025, down from $58.8 million as of December 31, 2024, indicating a decrease in liquidity [23] Business Line Data and Key Metrics Changes - The OCU400 program has shown positive two-year long-term safety and efficacy data, demonstrating a statistically significant improvement in visual function with a p-value of 0.005 [12] - The OCU410 program is on track for a Phase III clinical trial initiation in 2026, with a BLA submission expected in 2028 [10] - The OCU200 program for diabetic macular edema is currently in Phase I clinical trials, with plans to complete the trial in the second half of 2025 [21] Market Data and Key Metrics Changes - OCU400 has the potential to treat approximately 300,000 RP patients in the U.S. and EU, and 1.6 million patients globally, using a gene-agnostic approach [11] - OCU410 is designed to address multiple pathways implicated in the pathogenesis of dry AMD, targeting 2-3 million people in the U.S. and Europe, and 8 million globally [18] Company Strategy and Development Direction - The company aims to file three biologics license applications (BLA) in the next three years, focusing on modifier gene therapies that offer potential cures for large patient populations [8] - The strategy includes bringing manufacturing in-house after initial commercial launch, with plans for a second site in the U.S. [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress of their gene therapy programs and the importance of upcoming milestones, emphasizing the mission to provide one-time therapies for significant unmet medical needs [60] - The company is actively engaging with regulatory agencies to ensure alignment on clinical trial designs and submissions [41] Other Important Information - The company is exploring strategic partnerships for funding its vaccine technology for flu [22] - The EMA has granted eligibility for the OCU400 MAA submission, recognizing its potential to address serious unmet medical needs in Europe [14] Q&A Session Summary Question: Enrollment status for the Limelight study and filing targets - Management confirmed that enrollment is on track for the first half of 2025, with a BLA submission expected a year from now [28] Question: Manufacturing capabilities for filing and commercialization - Management stated that process validations at commercial scale are on target for completion this year, with plans to bring manufacturing in-house after initial launch [31][32] Question: Update on the OCU200 program - Management indicated that a clinical update, including preliminary efficacy and safety data, is expected before the end of the year [36] Question: Clarification on European regulations for OCU400 - Management clarified that no additional trials are required in Europe if approval is obtained in the U.S., as the trial has sufficient representation for global mutations [57] Question: Impact of changes at government agencies on clinical trials - Management reported no negative impact from recent changes at government agencies, maintaining strong engagement with NIAID for the clinical study plan [44] Question: Interim look for the Limelight study - Management confirmed that there is no interim look in the study, and full data will be available once the CSR is finalized [48]

Financial Data and Key Metrics Changes - Research and development expenses for Q1 2025 were $9.5 million, up from $6.8 million in Q1 2024, indicating a 39.7% increase [21] - General and administrative expenses for Q1 2025 were $6.5 million, slightly up from $6.4 million in the same period of 2024 [22] - Net loss for Q1 2025 was approximately $15.3 million, or $0.05 net loss per share, compared to a net loss of approximately $11.9 million, or $0.05 net loss per share in Q1 2024 [22] - Cash and restricted cash totaled $38.1 million as of March 31, 2025, down from $58.8 million as of December 31, 2024, indicating a significant decrease in liquidity [22] Business Line Data and Key Metrics Changes - The OCU400 program has shown positive two-year long-term safety and efficacy data, demonstrating a statistically significant improvement in visual function with a p-value of 0.005 [11] - OCU410 SD has received alignment with the FDA for a Phase II-III pivotal confirmatory trial, which could support a BLA submission in 2027 [8] - The OCU410 program for geographic atrophy (GA) has shown a 41% slower GA lesion growth in treated eyes compared to untreated eyes after a single injection [18] Market Data and Key Metrics Changes - OCU400 has the potential to treat approximately 300,000 RP patients in the U.S. and EU, and 1.6 million patients globally, using a gene-agnostic approach [10] - OCU410 is designed to address multiple pathways implicated in the pathogenesis of dry AMD, targeting 2-3 million people in the U.S. and Europe, and 8 million globally suffering from GA [17] Company Strategy and Development Direction - The company aims to file three biologics license applications (BLA) in the next three years, focusing on modifier gene therapies that offer potential cures for large patient populations [6] - The strategy includes building manufacturing capabilities in-house to support future commercial launches, with plans for a second site in the U.S. [31][32] - The company is exploring strategic partnerships and funding opportunities to enhance its working capital and support its vaccine technology development [22][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress of their gene therapy programs and the significance of upcoming milestones, emphasizing the mission to provide one-time therapies for life to address unmet medical needs [61] - The management highlighted the importance of ongoing discussions with regulatory agencies like the FDA and EMA to align clinical trial designs and expedite the approval process for their therapies [40] Other Important Information - The company is currently in discussions regarding developmental funding for its vaccine technology for influenza [21] - The investigational new drug application for OCU500 is in effect, with plans to initiate a Phase I clinical trial in Q2 2025 [20] Q&A Session Summary Question: Enrollment status of the Limelight study and filing targets - The enrollment for the OCU400 Phase III trial is on track for the first half of 2025, with a BLA submission expected a year from now [28] Question: Manufacturing capabilities for filing and commercialization - The company is on target to complete process validations at commercial scale this year, with plans to bring manufacturing in-house after initial commercial launch [30][31] Question: Update on the OCU200 program - The clinical trial for OCU200 is expected to be completed in the latter part of this year, with updates on preliminary efficacy and safety to be provided before year-end [34] Question: Clarification on clinical trials in Europe - No additional trials are required in Europe if approval is obtained in the U.S., as the current trial has sufficient representation for global mutations [58]

Core Insights - Ocugen, Inc. is advancing its novel modifier gene therapies for blindness diseases, with a goal of filing three Biologics License Applications (BLA) or Marketing Authorization Applications (MAA) within the next three years [2][6] Financial Performance - As of March 31, 2025, the company's cash and restricted cash totaled $38.1 million, down from $58.8 million as of December 31, 2024 [12] - Total operating expenses for Q1 2025 were $16.0 million, compared to $13.2 million in Q1 2024, with research and development expenses increasing from $6.8 million to $9.5 million [12] - The net loss per common share for Q1 2025 was $0.05, consistent with the loss per share reported in Q1 2024 [12][19] Clinical Development Updates - The Phase 3 liMeliGhT clinical trial for OCU400, targeting retinitis pigmentosa (RP), is open to all eligible patients and aims to treat approximately 300,000 RP patients in the U.S. and EU [3][12] - The company has received FDA alignment to proceed with a Phase 2/3 pivotal trial for OCU410ST for Stargardt disease, which affects around 100,000 individuals in the U.S. and EU [4][12] - In the Phase 2 portion of the OCU410 trial for geographic atrophy (GA), treated subjects showed a 4-line (23-letter) gain in visual acuity and 41% slower GA lesion growth compared to untreated eyes [5][12] Regulatory Progress - All three modifier gene therapies have received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA), which accelerates the regulatory review process [6][12] - The EMA has provided a positive opinion for the ATMP classification of OCU400, allowing for a centralized MAA submission [12] Future Plans - Ocugen plans to initiate the Phase 2/3 study for OCU410ST by mid-2025, with a target BLA filing in 2027 [4][12] - The company is also preparing to complete the Phase 1 clinical trial for OCU200, its candidate for diabetic macular edema, in the second half of 2025 [9][12]